X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Current Deferred Revenue came in at $1.4 million in Q2 2026, up 90.19% on a YoY basis from $754000.0 in Q2 2025, and up 39.63% quarter-over-quarter from $1.0 million in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Current Deferred Revenue for 3 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Deferred Revenue rose 90.19% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 90.19% YoY), and the FY2025 full-year result was $1.1 million, changed N/A from the prior year.
- Current Deferred Revenue rose to $1.4 million in Q2 2026 per XFOR's latest filing, from $1.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.4 million in Q2 2026 and bottomed at $592000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 754,000.00 |
| Mar 31, 2025 | 855,000.00 |
| Dec 31, 2018 | 93,000.00 |